



Source: Eikon Thomson Reuters

Market data	
EPIC/TKR	AVO
Price (p)	38.5
12m High (p)	64.0
12m Low (p)	31.0
Shares (m)	169.6
Mkt Cap (£m)	65.3
EV (£m)	58.3
Free Float*	48%
Market	AIM
	*As defined by AIM Rule 26

Description

Advanced Oncotherapy (AVO) is developing next-generation proton therapy systems for use in radiation treatment of cancers. The first system is expected to be installed in Harley Street, London, during 2019; it will be operated through a JV with Circle Health.

Company information							
Exec. Chairman	Michael Sinclair						
CEO	Nicolas Serandour						
	+44 203 617 8728						
	www.avoplc.com						

Key shareholde	ers			
Board & Management		13.0%		
Yantai CIPU		26.5%		
Brahma AG		5.3%		
AB Segulah		3.8%		
Hargreaves Lansdowne		3.6%		
Handelsbanken		3.5%		
Diary				
2Q'19		Finals		
1H'19	Harley St	reet ready		

Analysts				
Martin Hall	020 7194 7632			
mh@	hardmanandco.com			
Dorothea Hill	020 7194 7626			
dmh@	hardmanandco.com			
Grégoire Pavé	020 7194 7628			
gp@hardmanandco.com				

ADVANCED ONCOTHERAPY

Important regulatory milestone: ISO approval

AVO's goal is to deliver an affordable and novel proton therapy (PT) system, based on state-of-the-art technology developed originally at the CERN. Achievement of major technical milestones has boosted confidence, and the group remains on track with its strategy. AVO has integrated successfully the four types of structure that constitute the LIGHT accelerator and has recorded the proton beam at an energy of 52MeV, sufficient to treat superficial tumours. AVO has just achieved an important regulatory milestone by receiving ISO 13485 accreditation, demonstrating the company's commitment to safety and high quality, and further endorsing the team's ability to meet its objectives.

- Strategy: AVO is developing a compact and modular PT system at an affordable price for the payor, financially attractive to the operator, and generating superior patient outcomes. AVO benefits from the technology know-how developed by CERN and ADAM, Geneva, and relies on a base of world-class suppliers.
- ▶ **ISO approval:** ISO 13485 is an internationally agreed standard that sets out the requirements for a quality management system specific to the medical devices industry. It can also be used by internal and external parties, such as certification bodies, to help them with their auditing processes.
- Development update: Infrastructure to support the installation and assembly of the full LIGHT system has already started at STFC's Daresbury Laboratory. Once the complete system has been installed and validated, it will be used to support AVO's submission for CE marking, prior to first patients in 2020.
- Risks: With the £10m funding announced in December, AVO is maintening its ability to meet its objectives and keep the pace of its manufacturing plan. Execution risk remains, but the more complex technical challenges have been overcome, and integration of the remaining units is an easy step towards getting the LIGHT accelerator.
- Investment summary: Demand for PT is increasing worldwide, and the need for a small, flexible, affordable and close-to-patient system is desirable. AVO has attracted strong manufacturing and investment partners, and discussions with potential customers are advancing. Progress at the flagship Harley Street site has been substantial, and installation of the first LIGHT system is planned to start in mid-2019. The latest technical update has brought further assurance and boosted confidence.

Financial summary and valuation									
Year-end Dec (£000)	2015	2016	2017	2018E	2019E	2020E			
Sales	0.0	0.0	0.0						
Administration costs	-6.6	-11.2	-12.9						
Milestones/upfronts	0.0	0.0	0.0						
EBITDA	-6.4	-10.8	-12.6						
Underlying EBIT	-6.6	-11.2	-12.9						
Reported EBIT	-8.5	-13.1	-14.5	Forecas	sts under r	review			
Underlying PBT	-6.7	-11.3	-14.9						
Statutory PBT	-8.6	-13.2	-16.5						
Underlying EPS (p)	-7.1	-13.9	-15.6						
Statutory EPS (p)	-12.3	-14.4	-18.9						
Net (debt)/cash	8.0	0.9	-9.2						
Capital increase	21.1	13.5	7.3						
Net (debt)/cash	8.0	0.9 13.5	-9.2 7.3	tman & Co	lifa Scianca	c Pacagro			

Source: Hardman & Co Life Sciences Research



In line with best practice

ISO 13485:2016 certification

As far as the International Organisation for Standards (ISO) is concerned, safety and quality are non-negotiable in the medical devices industry. Regulatory requirements are increasingly stringent throughout every step of a product's life cycle, including service and delivery. Therefore, industry manufacturers are expected to demonstrate that their management processes are of the highest quality and in line with 'best practice'. ISO 13485:2016 certification is recognition that these high standards are being followed. Compliance with ISO certification is a pre-requisite for getting CE marking approval and the authorisation to sell the LIGHT system in Europe.

Who is ISO 13485 for?

ISO 13485 is designed to be used by organisations involved in the design, production, installation and servicing of medical devices – such as an instrument, machine, implant or *in vitro* reagent – intended for use in the diagnosis, prevention and treatment of diseases or other medical conditions. It can also be used by internal and external parties, such as certification bodies, to help them with their auditing processes.


Certification to ISO 13485

The ISO certification is undertaken by a third party that has independently examined the management processes and validated that the company has met the requirements of the standard.

AVO has announced that it has received ISO 13485 certification from Lloyd's Register, an independent compliance specialist, following an audit of its processes. Certification of this standard represents an important milestone in the development of LIGHT, demonstrating the company's commitment to safety and high quality.

Development update

Enormous progress was made during 2018, and AVO hit a number of milestones that greatly de-risked the whole project. LIGHT has reached the stage where the four components (the proton source, the RFQ, the SCDTLs and the CCLs) that constitute the accelerator have been integrated at its Geneva testing site and accelerated the proton beam to an energy level of >50MeV, which would be sufficient to treat superficial tumours. While certain testing is still being undertaken, on a broader front, sufficient testing has taken place to show proof-of-concept.



Source: Advanced Oncotherapy investor presentation



Next steps

A number of actions will be undertaken during 2019 to generate the first complete LIGHT system, which will be used to obtain regulatory approval, via CE marking:

- Daresbury site: In May 2018, a lease was signed between AVO and the UK Government's Science and Technology Facilities Council (STFC) to establish a UK testing and assembly site at Daresbury (Cheshire). The facility will be used to test and assemble a complete and operational version of the LIGHT system for verification and validation for regulatory approval (CE Mark).
- ▶ Geneva: The ADAM site in Geneva is where AVO's R&D facility is located. Sufficient testing has been undertaken to provide proof-of-concept, and the design of all the accelerating structures has been validated.
- LIGHT: The infrastructure work has already started at Daresbury, together with the assembling of the LIGHT system, as both are meant to be built in parallel. The concrete shielding for the proton injector and RF test bunkers is already in place, and delivery of the components has already occurred.



Source: STFC on Twitter, 16 January 2019

AVO is in regular discussions with its Notified Body. On completion of the verification and validation of the LIGHT system, AVO expects to receive CE marking from the Medical and Healthcare products Regulatory Agency (MHRA). Important within this process is the third-party ISO 13485 certification, which demonstrates to regulators that AVO has met the stringent requirements of the standard. We expect AVO to have all the accelerating structures of LIGHT integrated before end-2019, with submission for CE marking happening afterwards. This system will then be dismantled for re-construction at the Harley Street site, with the expectation of first treatments in 2020.

Funding update

In December 2018, AVO announced its intention to raise £10.0m gross new capital through the issue of 25.0m new Ordinary shares at 40p per share, via a Subscription with existing and new shareholders. Admission to AIM is conditional on the passing of certain resolutions at a general meeting to be held today. The subscription was led by DNCA Investments, which is investing £4.8m into the company, giving it 6.2% of the enlarged share capital.

Following the Admission on AIM of the Subscription shares, AVO will have 194.566m shares in issue.

Advanced Oncotherapy



Disclaimer

Hardman & Co provides professional independent research services and all information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. However, no guarantee, warranty or representation, express or implied, can be given by Hardman & Co as to the accuracy, adequacy or completeness of the information contained in this research and they are not responsible for any errors or omissions or results obtained from use of such information. Neither Hardman & Co, nor any affiliates, officers, directors or employees accept any liability or responsibility in respect of the information which is subject to change without notice and may only be correct at the stated date of their issue, except in the case of gross negligence, fraud or wilful misconduct. In no event will Hardman & Co, its affiliates or any such parties be liable to you for any direct, special, indirect, consequential, incidental damages or any other damages of any kind even if Hardman & Co has been advised of the possibility thereof.

This research has been prepared purely for information purposes, and nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The research reflects the objective views of the analyst(s) named on the front page and does not constitute investment advice. However, the companies or legal entities covered in this research may pay us a fixed fee in order for this research to be made available. A full list of companies or legal entities that have paid us for coverage within the past 12 months can be viewed at http://www.hardmanandco.com/legals/research-disclosures. Hardman may provide other investment banking services to the companies or legal entities mentioned in this report.

Hardman & Co has a personal dealing policy which restricts staff and consultants' dealing in shares, bonds or other related instruments of companies or legal entities which pay Hardman & Co for any services, including research. No Hardman & Co staff, consultants or officers are employed or engaged by the companies or legal entities covered by this document in any capacity other than through Hardman & Co.

Hardman & Co does not buy or sell shares, either for their own account or for other parties and neither do they undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly, they do not publish records of their past recommendations. Where a Fair Value price is given in a research note, such as a DCF or peer comparison, this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities, companies and legal entities but has no scheduled commitment and may cease to follow these securities, companies and legal entities without notice.

The information provided in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hardman & Co or its affiliates to any registration requirement within such jurisdiction or country.

Some or all alternative investments may not be suitable for certain investors. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment. Investments may be leveraged and performance may be volatile; they may have high fees and expenses that reduce returns. Securities or legal entities mentioned in this document may not be suitable or appropriate for all investors. Where this document refers to a particular tax treatment, the tax treatment will depend on each investor's particular circumstances and may be subject to future change. Each investor's particular needs, investment objectives and financial situation were not taken into account in the preparation of this document and the material contained herein. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this document various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances.

This document constitutes a 'financial promotion' for the purposes of section 21 Financial Services and Markets Act 2000 (United Kingdom) ('FSMA') and accordingly has been approved by Capital Markets Strategy Ltd which is authorised and regulated by the Financial Conduct Authority (FCA).

No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording or otherwise, without prior permission from Hardman & Co. By accepting this document, the recipient agrees to be bound by the limitations set out in this notice. This notice shall be governed and construed in accordance with English law. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the FCA under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

(Disclaimer Version 8 – Effective from August 2018)

Status of Hardman & Co's research under MiFID II

Some professional investors, who are subject to the new MiFID II rules from 3rd January, may be unclear about the status of Hardman & Co research and, specifically, whether it can be accepted without a commercial arrangement. Hardman & Co's research is paid for by the companies, legal entities and issuers about which we write and, as such, falls within the scope of 'minor non-monetary benefits', as defined in the Markets in Financial Instruments Directive II.

In particular, Article 12(3) of the Directive states: 'The following benefits shall qualify as acceptable minor non-monetary benefits only if they are: (b) 'written material from a third party that is commissioned and paid for by a corporate issuer or potential issuer to promote a new issuance by the company, or where the third party firm is contractually engaged and paid by the issuer to produce such material on an ongoing basis, provided that the relationship is clearly disclosed in the material and that the material is made available at the same time to any investment firms wishing to receive it or to the general public...'

The fact that Hardman & Co is commissioned to write the research is disclosed in the disclaimer, and the research is widely available.

The full detail is on page 26 of the full directive, which can be accessed here: <u>http://ec.europa.eu/finance/docs/level-2-measures/mifid-delegated-regulation-2016-2031.pdf</u>

In addition, it should be noted that MiFID II's main aim is to ensure transparency in the relationship between fund managers and brokers/suppliers, and eliminate what is termed 'inducement', whereby free research is provided to fund managers to encourage them to deal with the broker. Hardman & Co is not inducing the reader of our research to trade through us, since we do not deal in any security or legal entity.

research@hardmanandco.com

35 New Broad Street London EC2M 1NH

+44(0)20 7194 7622

www.hardmanandco.com